Glycemic Variability in Pancreatogenic Diabetes Mellitus: characteristics, Risks, Potential Mechanisms, and Treatment Possibilities
Yuyan Sun,Bing Lu,Yuanwen Hu,Yingqi Lv,Shao Zhong
DOI: https://doi.org/10.2147/ijgm.s477497
IF: 2.145
2024-09-22
International Journal of General Medicine
Abstract:Yuyan Sun, 1 Bing Lu, 1 Yuanwen Hu, 2 Yingqi Lv, 3 Shao Zhong 1 1 Department of Endocrinology, Gusu School, Nanjing Medical University, The First People's Hospital of Kunshan, Kunshan, 215300, People's Republic of China; 2 Department of Gastroenterology, The First People's Hospital of Kunshan, Kunshan, 215300, People's Republic of China; 3 Division of Endocrinology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, 210009, People's Republic of China Correspondence: Shao Zhong, Department of Endocrinology, Gusu School, Nanjing Medical University, the First People's Hospital of Kunshan, Kunshan, 215300, People's Republic of China, Tel +86 13328056828, Email In recent years, pancreatogenic diabetes mellitus has garnered significant attention due to its high incidence, complications, and mortality rates. Glycemic variability (GV) can increase the risk of pancreatogenic diabetes mellitus and its associated complications; however, the precise mechanism remains unclear. The effective control of GV is crucial for preventing the onset of pancreatic diabetes mellitus and improving prognosis. Both diet and antidiabetic medications have substantial effects on GV. However, many patients are prescribed suboptimal or even harmful drugs. Therefore, to provide a comprehensive treatment basis for clinicians to prevent and treat pancreatogenic diabetes mellitus, this study aimed to elucidate the relationship between GV and pancreatogenic diabetes mellitus; investigate the potential mechanisms (such as oxidative stress, inflammatory response, insulin resistance, and lipid metabolism disorders); provide lifestyle guidance; and recommend drug selections to reduce the GV in patients with pancreatogenic diabetes mellitus. Keywords: pancreatogenic diabetes, glucose fluctuation, glycemic variability, therapy, antihyperglycemic drug Graphical Pancreatogenic diabetes mellitus (DM), also known as type 3c DM (T3cDM), is a type of diabetes caused by exocrine pancreatic disease. 1,2 Based on etiology, it can be primarily categorized as post-pancreatitis DM (PPDM, including post-acute pancreatitis DM [PPDM-A] and post-chronic pancreatitis DM [PPDM-C]), pancreatic cancer-related diabetes (PCRD), and cystic fibrosis-related diabetes. 3 Studies have shown that T3cDM has become the second most common type of diabetes in adults after type 2 DM (T2DM), surpassing the prevalence of type 1 diabetes (T1DM). 4,5 The projected incidence of T3cDM is expected to reach 16 individuals per 100,000 by 2050, indicating an average annual growth rate of approximately 3%. 6 Patients with T3cDM exhibit a worse prognosis than that of individuals with T2DM. Compared with patients with T2DM, these patients have significantly higher risks of pancreatic cancer, hypoglycemia, microvascular and macrovascular complications, and all-cause mortality 7,8 and a shorter life expectancy. 9 Pancreatic exocrine diseases can impair the pancreatic islet function, leading to the dysregulation of insulin secretion. This impairment can lead to abnormal glucose metabolism, characterized by elevated blood glucose levels and irregular blood glucose fluctuations. Patients with exocrine pancreatic diseases are prone to hypoglycemia due to their specific pathological mechanism, coupled with the destruction of pancreatic islet α-cells, insufficient glucagon secretion, and impaired hypoglycemic antagonistic regulatory mechanism, as well as alcoholism and poor compliance, leading to significant fluctuations in blood glucose levels. Previous studies have reported a significant correlation between abnormal glucose fluctuations and worsening clinical outcomes in hospitalized patients. 10,11 Abnormal glucose fluctuations during the early course of pancreatitis increase the risk of PPDM. 12 In addition, excessive glucose fluctuations increase the risk of complications in patients with DM. Therefore, patients with T3cDM require lifestyle modification and medication treatment to reduce glucose fluctuations before and after disease onset. This study examined the relationship between glucose fluctuations and T3cDM. We also discussed the lifestyle and medication management strategies that can help reduce blood glucose fluctuations in patients with T3cDM. This study aimed to investigate the influence of glucose fluctuations on the development of T3cDM, to prevent the onset and progression of T3cDM, and to enhance the disease prognosis. This review utilized the following search terms: (pancreatogenic OR pancreatogenous OR type 3c OR pancreatitis OR post-pancreatitis) AND (diabetes OR diabetes mellitus) AND (glucose fluctuation OR glycemic variability). PubMed, Web of Science, China National Knowledg -Abstract Truncated-
medicine, general & internal